Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data from ALERT Study, and Announces Notice of Allowance for Key Lixivaptan U.S. Patent Application
December 14, 2021 07:30 ET
|
Centessa Pharmaceuticals plc
~ Initiation of registrational Phase 3 ACTION clinical study with lixivaptan is an important milestone to bring this potential new treatment option to ADPKD patients ~ ~ All four subjects in the...
Centessa Pharmaceuticals Announces Addition to NASDAQ Biotechnology Index
December 13, 2021 16:15 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to...
Centessa Pharmaceuticals Announces Third Quarter 2021 Financial Results and Business Updates
November 15, 2021 07:00 ET
|
Centessa Pharmaceuticals plc
~ Announced positive topline data from proof-of-concept study of SerpinPC in severe hemophilia A and B subjects not on prophylaxis, demonstrating 88% reduction in median Annualized Bleeding Rate...
Centessa Pharmaceuticals to Present at Upcoming Conferences in 2021
November 10, 2021 16:45 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA) today announced that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the...
Centessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1 Study Evaluating ZF874
November 01, 2021 07:30 ET
|
Centessa Pharmaceuticals plc
~ First demonstration that a pharmacological chaperone can provide sufficient functional Z-A1AT increases to potentially achieve greater than 11 micromolar levels in individuals with PiZZ genotype ~ ...
Orexia Therapeutics, empresa filial de Centessa Pharmaceuticals, y Schrödinger anuncian una colaboración para descubrir nuevos agonistas de los receptores de orexina
October 20, 2021 12:01 ET
|
Centessa Pharmaceuticals plc
~ El trabajo de investigación se centrará en moléculas pequeñas con perfiles clínicos diferenciados para aprovechar el gran potencial del agonismo de la orexina en distintas indicaciones ~ ~ Es la...
Дочерняя компания Centessa Pharmaceuticals, Orexia Therapeutics и Schrödinger объявляют о сотрудничестве для открытия новых агонистов рецепторов орексина
October 20, 2021 12:01 ET
|
Centessa Pharmaceuticals plc
~ Исследования будут сосредоточены на малых молекулах с дифференцированными клиническими профилями, чтобы использовать широкий потенциал агонизма орексина по разным показаниям ~ ~ Впервые Schrödinger...
La consociata di Centessa Pharmaceuticals, Orexia Therapeutics, e Schrödinger annunciano una collaborazione per studiare nuovi agonisti del recettore dell'oressina
October 20, 2021 12:01 ET
|
Centessa Pharmaceuticals plc
~ La ricerca si concentrerà su piccole molecole con profili clinici differenziati per sfruttare l'ampio potenziale dell'agonismo dell'oressina per diverse indicazioni terapeutiche ~ ~ Per la prima...
Orexia Therapeutics, filiale de Centessa Pharmaceuticals, et Schrödinger annoncent une collaboration visant à découvrir de nouveaux agonistes des récepteurs de l'orexine
October 20, 2021 12:01 ET
|
Centessa Pharmaceuticals plc
~ Les efforts de découverte se concentreront sur de petites molécules avec des profils cliniques différenciés dans le but d'exploiter le vaste potentiel de l'agonisme de l'orexine à travers...
Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics en Schrödinger kondigen samenwerking aan om nieuwe orexine-receptoragonisten te ontdekken
October 20, 2021 12:01 ET
|
Centessa Pharmaceuticals plc
~ De ontdekkingsinspanningen richten zich op kleine moleculen met gedifferentieerde klinische profielen om het brede potentieel van orexine-agonisme te benutten bij verschillende indicaties ~ ~ De...